登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Tris-CAR-T Cell Therapy for Recurrent Glioblastoma
ClinicalTrials.gov 上登记的一项胶质瘤开放试验,由首都医科大学附属北京天坛医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT05577091,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 70 岁;性别:不限
登记记录的入选字段
Patients with history of glioblastoma are diagnosed with recurrent glioblastoma and residual tumor after intracranial tumor resection/biopsy performed in Beijing Tiantan Hospital.
入选标准第 2 条
Patients who finished radiotherapy or temozolomide/bevacizumab or other drugs for at least 4 weeks. All toxicities of prior treatment should be defined as less than or equal to grade 1 (except for toxicities such as hair loss or leukoplakia) according to the Common Terminology Standard for Adverse Events (CTCAE 5.0).
入选标准第 3 条
Kanovsky Performance Status (KPS) ≥ 70.
入选标准第 6 条
Kanovsky Performance Status (KPS) ≤ 70.
排除标准第 1 条
White blood cells (WBC) > 3.50×10\^9/L (performed within 14 days prior to PBMC collection unless otherwise noted).
入选标准第 8 条
Platelet ≥ 200×10\^9/L (performed within 14 days prior to PBMC collection unless otherwise noted).
入选标准第 9 条
Hemoglobin ≥ 120 g/L (performed within 14 days prior to PBMC collection unless otherwise noted).
入选标准第 10 条
Total bilirubin ≤ 20 μmol/L (performed within 14 days prior to PBMC collection unless otherwise noted).
入选标准第 11 条
Aspartic acid aminotransferase (AST) ≤ 2.5×42 U/L (performed within 14 days prior to PBMC collection unless otherwise noted).
入选标准第 12 条
Alanine aminotransferase (ALT) ≤ 2.5×41 U/L (performed within 14 days prior to PBMC collection unless otherwise noted).
入选标准第 13 条
Serum creatinine ≤ 90 μmol/L (performed within 14 days prior to PBMC collection unless otherwise noted).
入选标准第 14 条
Fertile women: a negative serum pregnancy test (performed within 14 days prior to PBMC collection unless otherwise noted).
入选标准第 17 条
The patient agrees that contraception should be used in patients of childbearing age for at least 3 months from screening to the last infusion of Tris-CAR-T cells. The period of childbearing age is defined as unsurgically neutered (men and women) or without menopause for more than 1 year (women only).
入选标准第 18 条
Special cases: pregnancy or lactation.
排除标准第 13 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05577091,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age: 18 years to 70 years (including cut-off values). Patients with history of glioblastoma are diagnosed with recurrent glioblastoma and residual tumor after intracranial tumor resection/biopsy performed in Beijing Tiantan Hospital. Patients who finished radiotherapy or temozolomide/bevacizumab or other drugs for at least 4 weeks. All toxicities of prior treatment should be defined as less than or equal to grade 1 (except for toxicities such as hair loss or leukoplakia) according to the Common Terminology Standard for Adverse Events (CTCAE 5.0). Patients who is suitable for craniotocerebrospinal fluid shunt and attachment (Ommaya device) implantation confirmed by a competent physician. Patients and/or legal representative is able to sign written informed consent. Kanovsky Performance Status (KPS) ≥ 70. According to the researchers' judgment, the life expectancy ≥ 8 weeks. White blood cells (WBC) > 3.50×10\^9/L (performed within 14 days prior to PBMC collection unless otherwise noted). Platelet ≥ 200×10\^9/L (performed within 14 days prior to PBMC collection unless otherwise noted). Hemoglobin ≥ 120 g/L (performed within 14 days prior to PBMC collection unless otherwise noted). Total bilirubin ≤ 20 μmol/L (performed within 14 days prior to PBMC collection unless otherwise noted). Aspartic acid aminotransferase (AST) ≤ 2.5×42 U/L (performed within 14 days prior to PBMC collection unless otherwise noted). Alanine aminotransferase (ALT) ≤ 2.5×41 U/L (performed within 14 days prior to PBMC collection unless otherwise noted). Serum creatinine ≤ 90 μmol/L (performed within 14 days prior to PBMC collection unless otherwise noted). Blood oxygen saturation ≥ 95% (performed within 14 days prior to PBMC collection unless otherwise noted). Seronegative of the combination of human immunodeficiency virus (HIV) antibody (Ab) (performed within 14 days prior to PBMC collection unless otherwise noted). Fertile women: a negative serum pregnancy test (performed within 14 days prior to PBMC collection unless otherwise noted). The patient agrees that contraception should be used in patients of childbearing age for at least 3 months from screening to the last infusion of Tris-CAR-T cells. The period of childbearing age is defined as unsurgically neutered (men and women) or without menopause for more than 1 year (women only).排除标准:Exclusion Criteria:
Kanovsky Performance Status (KPS) ≤ 70. Highly allergic constitution or severe allergies history. Those who have psychiatric or psychological diseases and cannot cooperate with treatment and efficacy assessment. Receive other drug trials within 60 days before enrollment, or receive other routine treatment in non-experimental designs for glioblastoma, such as stereotactic radiation therapy or placement of carmustine wafers. Combined with infection, active infection, fever of unknown cause. Combined with serious or unstable heart, lung, liver, kidney and hematopoietic system diseases, including active hepatitis. Combined with inflammation and immune system diseases (such as rheumatoid arthritis), or known immunosuppressive diseases. Combined with neurological diseases, such as diffuse leptomeningeal disease, or neurodegenerative diseases. Known allergies to immunotherapy and related cellular products. Patients who have received any gene therapy before. Long-term use of immunosuppressants is required for any reason. Patients with a history of organ transplantation or who are waiting for organ transplantation. Special cases: pregnancy or lactation. Other circumstances in which the investigators believe the patient is unsuitable for this trial.
引自 ClinicalTrials.gov, NCT05577091, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05577091,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。